List of Excipients in Branded Drug ROWEEPRA

Generic Drugs Containing ROWEEPRA

Company	Ingredient	NDC	Excipient
OWP Pharmaceuticals Inc	levetiracetam	69102-108	FD&C BLUE NO. 2
OWP Pharmaceuticals Inc	levetiracetam	69102-108	HYPROMELLOSES
OWP Pharmaceuticals Inc	levetiracetam	69102-108	MAGNESIUM STEARATE
OWP Pharmaceuticals Inc	levetiracetam	69102-108	POLYETHYLENE GLYCOL 400
OWP Pharmaceuticals Inc	levetiracetam	69102-108	POVIDONE K30
OWP Pharmaceuticals Inc	levetiracetam	69102-108	SILICON DIOXIDE
OWP Pharmaceuticals Inc	levetiracetam	69102-108	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in ROWEEPRA?

# Of NDCs	Excipient
1	FD&C BLUE NO. 2
1	HYPROMELLOSES
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 400
1	POVIDONE K30
1	SILICON DIOXIDE
1	SODIUM STARCH GLYCOLATE TYPE A POTATO

ROWEEPRA Excipient Strategy and Commercial Opportunities for Levetiracetam

Last updated: August 4, 2026

ROWEEPRA is a levetiracetam immediate-release product used for seizure treatment. Its commercial opportunity is not based on new-molecule exclusivity. Levetiracetam is an established generic active ingredient with low formulation complexity, broad supplier availability, and limited patent protection around the immediate-release product. The strongest opportunities are differentiated excipient systems for pediatric use, taste masking, swallowability, dose flexibility, stability, and supply-chain resilience.

The most attractive development paths are oral liquid optimization, orally disintegrating or mini-tablet formats, lower-burden tablet coatings, and excipient substitutions that preserve bioequivalence while reducing cost or improving patient acceptance.

What is ROWEEPRA and which active ingredient does it contain?

ROWEEPRA contains levetiracetam, an antiepileptic drug marketed in immediate-release tablet and oral-solution formats. Levetiracetam is also sold under brands including Keppra and under multiple generic labels. The FDA-approved product category includes tablets, oral solutions, extended-release tablets, and orally disintegrating products. [1]

Product attribute	ROWEEPRA position
Active ingredient	Levetiracetam
Therapeutic class	Antiepileptic
Primary use	Adjunctive treatment of partial-onset seizures and other approved seizure indications, depending on dosage form and label
Immediate-release strengths	Commonly 250 mg, 500 mg, 750 mg, and 1,000 mg tablets
Oral liquid strength	Commonly 100 mg/mL
Administration	Oral
Regulatory pathway	Generic drug pathway for levetiracetam products
Primary formulation opportunity	Pediatric-friendly liquid and flexible solid dosage forms
Main commercial constraint	Mature generic market and limited product-level exclusivity

The ROWEEPRA label identifies conventional tablet excipients, including binders, disintegrants, lubricants, glidants, coating materials, and colorants. The oral solution uses a liquid vehicle, sweetening agents, buffering components, preservatives, and flavoring materials. Exact excipient composition must be assessed against the current approved package insert and product-specific regulatory filing. [2]

What excipients are used in ROWEEPRA formulations?

ROWEEPRA tablets use a conventional immediate-release excipient platform. The formulation objective is rapid disintegration, uniform drug distribution, mechanical strength, acceptable coating performance, and stable dissolution across the product shelf life.

Typical excipient functions include:

Excipient function	Commercial purpose in ROWEEPRA-type tablets
Diluent	Provides tablet mass and improves compression
Binder	Supports granule and tablet strength
Disintegrant	Promotes breakup after administration
Lubricant	Reduces sticking and ejection force
Glidant	Improves powder flow and content uniformity
Film former	Protects the tablet and improves appearance
Plasticizer	Improves coating flexibility
Opacifier or colorant	Supports product identification and light protection

For oral solution products, the excipient system has a different risk profile. A typical levetiracetam liquid formulation may contain purified water, polyols or other sweetening agents, buffering salts, acidulants, preservatives, and flavoring agents. The major technical risks are taste, preservative effectiveness, microbial control, chemical stability, container compatibility, and dosing accuracy.

Levetiracetam is highly soluble relative to many small-molecule oral drugs. That reduces the need for complex solubilization technology. Commercial value therefore shifts toward sensory performance, formulation robustness, manufacturing efficiency, and patient usability.

What excipient strategy is most valuable for ROWEEPRA tablets?

The highest-value tablet strategy is a low-cost, robust immediate-release formulation that improves swallowing without creating dissolution or bioequivalence risk.

Tablet size reduction

Levetiracetam tablets can become large at higher strengths. A 1,000 mg dose creates a direct burden because patients may need multiple tablets or a large single unit. Opportunities include:

• Higher drug loading through direct compression or optimized granulation
• Low-density excipients that maintain tablet volume control
• Functional co-processed excipients that improve flow and compressibility
• Bilayer or multilayer formats for dose flexibility
• Scored tablets where permitted by the product design and regulatory filing

A smaller tablet can improve adherence, but aggressive drug loading may cause capping, friability, poor weight uniformity, or slower disintegration. The commercial objective is not maximum loading alone. It is a stable balance among tablet size, compression force, dissolution, and manufacturing yield.

Swallowability coatings

A smooth, low-friction film coating can improve administration for adults and adolescents. Polymeric coating systems may use hypromellose or comparable film-forming materials with plasticizers and pigments. Coating weight should remain low enough to avoid delayed dissolution.

Potential differentiation includes:

• Low-friction coating
• Reduced tablet roughness
• Moisture-barrier coating
• Color coding by strength
• Improved resistance to chipping and abrasion
• Lower coating time and reduced solvent burden

These changes are generally easier to commercialize than novel drug-delivery systems because they can remain within an immediate-release product profile.

Excipient substitution

Generic manufacturers can reduce cost and supply risk by qualifying multiple sources for magnesium stearate, colloidal silicon dioxide, croscarmellose sodium, povidone, hypromellose, polyethylene glycol, and pigments. Substitution must be assessed for:

• Particle-size distribution
• Moisture content
• Lubrication sensitivity
• Blend uniformity
• Compression behavior
• Dissolution profile
• Extractables and leachables
• Stability under accelerated conditions

Excipient substitution can create a meaningful manufacturing advantage even when it does not create a separate patent position.

What excipient strategy is most valuable for ROWEEPRA oral solution?

The oral solution offers the clearest product-development opportunity because taste and dosing convenience affect pediatric and geriatric use directly.

Taste masking

Levetiracetam oral solution products commonly require flavoring and sweetening systems to address active-ingredient taste. A commercially attractive formulation would improve palatability without excessive sugar, alcohol, or preservative load.

Possible strategies include:

• High-intensity sweetener systems
• Polyol-based sweetness and mouthfeel
• Flavor combinations selected through pediatric sensory testing
• Ion-exchange resin complexes
• Cyclodextrin inclusion systems
• Microparticulate taste-masking systems
• pH optimization to reduce bitterness perception
• Viscosity adjustment to reduce rapid taste exposure

A resin-complex or microparticle approach could provide stronger taste masking than simple flavor addition. It also introduces risks involving release kinetics, sedimentation, dose uniformity, filterability, and bioequivalence.

Sugar-free and low-calorie positioning

A sugar-free product can be attractive for children with dental-risk concerns and for patients requiring reduced sugar intake. Polyols, sucralose, acesulfame potassium, or other sweetening systems may be used, subject to tolerance and regulatory acceptability.

Key development controls include:

• Gastrointestinal tolerance of polyols
• Preservative performance
• Viscosity and pourability
• Compatibility with oral syringes
• Stability after repeated opening
• Taste at the highest labeled dose
• Accurate measurement across the full dosing range

Sugar-free positioning is commercially useful, but it must not create a high excipient burden that makes the product less acceptable to caregivers.

Pediatric dosing accuracy

A calibrated oral syringe is often more commercially important than a marginal flavor improvement. The product should support accurate measurement at low and high doses, with a bottle adapter that prevents leakage and minimizes residual hold-up.

Design opportunities include:

• Low-dead-volume bottle adapters
• Dose-marked oral syringes
• Multiple syringe sizes
• Improved bottle ergonomics
• Tamper-evident closures
• Child-resistant packaging with caregiver usability
• Labeling that minimizes dose-conversion errors

Packaging and device choices can create a differentiated product experience without changing the active ingredient.

Which formulations are protected by patents?

Immediate-release levetiracetam has limited composition-of-matter protection because the molecule and core product have been available for many years. The main historical patent and exclusivity issues concerned the active ingredient, branded Keppra products, extended-release technology, and certain dosage forms rather than conventional ROWEEPRA immediate-release tablets.

Protection category	Relevance to ROWEEPRA
Levetiracetam compound patents	Historically important, but generally expired or no longer a major barrier in the United States
Immediate-release tablet patents	Limited practical barrier in a mature generic market
Oral-solution formulation patents	Potentially relevant if a product uses novel taste masking, preservative, or delivery technology
Extended-release patents	More relevant to XR products than to immediate-release ROWEEPRA
Orally disintegrating tablet patents	Potentially relevant to differentiated dosage forms
Device and packaging patents	May protect bottle adapters, syringes, or dosing systems
Manufacturing patents	May protect continuous processing, granulation, or impurity-control methods

The strongest protectable position for a new ROWEEPRA-related product would likely come from a specific formulation claim covering a defined excipient range, taste-masking system, particle architecture, dissolution profile, or packaging-device combination. A generic listing of conventional excipients would have weak patent strength.

When does ROWEEPRA lose exclusivity?

ROWEEPRA does not have the commercial profile of a newly approved innovator product. Levetiracetam has long been subject to generic competition, and the immediate-release product is commercially mature. FDA generic approval permits multiple manufacturers to market products that demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [3]

The relevant exclusivity framework is therefore:

Exclusivity issue	Commercial assessment
New chemical entity exclusivity	No longer relevant to levetiracetam
Five-year NCE exclusivity	Expired
Three-year clinical-investigation exclusivity	Not a current barrier for standard levetiracetam tablets
Pediatric exclusivity	Historical or product-specific, not a general barrier to mature generic supply
Patent exclusivity	Primarily relevant to specific historical or modified-release products
Generic competition	Established
Biosimilar risk	Not applicable because levetiracetam is a small-molecule drug

The product’s commercial exposure is driven by price competition, manufacturing reliability, wholesaler access, pharmacy substitution, and supply contracts rather than by loss of a near-term patent cliff.

What is the Orange Book status of ROWEEPRA?

The FDA Orange Book primarily identifies approved drug products, therapeutic equivalence information, patents, and exclusivity associated with approved applications. [4] ROWEEPRA’s regulatory position should be assessed by identifying its specific application number, dosage form, strength, and reference-listed-drug relationship.

For a generic levetiracetam product, the principal Orange Book implications are:

1. The product may be listed as therapeutically equivalent to the reference product if FDA criteria are satisfied.
2. The product’s ANDA status does not create independent new-molecule exclusivity.
3. Any patent certifications would relate to patents listed for the reference product or applicable approved product.
4. Immediate-release levetiracetam has a lower patent risk profile than modified-release or novel delivery products.

A product-specific conclusion on Orange Book patent listings requires review of the current FDA listing for the relevant application and strength. The label alone does not establish the full patent-certification record.

Are there Paragraph IV challenges involving ROWEEPRA?

Paragraph IV litigation is more likely to affect innovator levetiracetam products, extended-release products, or branded formulations than an established generic label such as ROWEEPRA. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman framework, a first-filed ANDA applicant may receive 180-day generic exclusivity in qualifying circumstances. [5]

For ROWEEPRA, the principal risk categories are:

• A competing ANDA challenging a patent covering an associated formulation
• Litigation involving an extended-release levetiracetam product
• Disputes over polymorphs, particle size, manufacturing processes, or dosage-form claims
• Patent disputes involving a novel oral liquid or taste-masking system
• Contract or supply disputes unrelated to patent validity

No general biosimilar challenge applies. Levetiracetam is a chemically synthesized small molecule, so competitors use the ANDA pathway rather than the biosimilar pathway.

How strong is the patent estate for ROWEEPRA?

The patent estate for a conventional immediate-release ROWEEPRA product is likely weak unless the sponsor owns specific patents covering a proprietary formulation, device, or manufacturing process.

Patent asset	Relative strength
Conventional tablet excipient combination	Low
Standard film coating	Low
Sugar-free oral solution using known sweeteners	Low to moderate
Defined taste-masking complex	Moderate to strong if supported by data
Novel orally disintegrating formulation	Moderate
Dosing syringe or bottle adapter	Moderate, usually narrow
Manufacturing process with impurity reduction	Moderate if difficult to design around
Extended-release delivery system	Stronger, but outside standard immediate-release ROWEEPRA

A defensible formulation patent should include measurable technical limitations. Examples include dissolution at specified time points, impurity thresholds, particle-size ranges, stability results, taste scores, preservative effectiveness, or a defined relationship between excipient concentration and drug release.

Broad claims to "a levetiracetam formulation comprising a sweetener and flavor" would face substantial validity and obviousness risk.

What commercial opportunities exist for ROWEEPRA excipients?

Pediatric oral liquid platform

The best near-term opportunity is a palatable, sugar-free oral solution with robust preservative performance and accurate dosing. The target customers are pediatric prescribers, caregivers, specialty pharmacies, and hospitals.

Commercial advantages may include:

• Better acceptance by children
• Fewer administration refusals
• Lower dosing error risk
• Improved pharmacy differentiation
• Potential contract opportunities with hospital systems
• Reduced reliance on a single flavor or preservative supplier

Orally disintegrating and mini-tablet products

An orally disintegrating tablet or mini-tablet could address patients who cannot swallow conventional tablets but do not need a liquid. This format may reduce caregiver burden and improve portability.

The development program would need to control:

• Rapid disintegration
• Mouthfeel
• Residual bitterness
• Moisture sensitivity
• Tablet friability
• Packaging protection
• Dose flexibility

Excipient supply-chain localization

Because levetiracetam is a high-volume generic, qualified alternate sources can protect margin. Commercial opportunities include regional supply of:

• Direct-compression excipients
• Co-processed excipients
• Low-moisture disintegrants
• Functional coating systems
• Pediatric flavor systems
• Preservatives and buffering agents
• Oral-syringe and closure components

Supplier qualification can produce greater economic value than a narrow formulation patent if the product competes primarily on price and availability.

Hospital and institutional packaging

Unit-dose packaging, barcoded bottles, oral syringes, and tamper-evident formats can support institutional purchasing. A formulation that remains stable in smaller or single-use containers may reduce waste and improve medication-management workflows.

How does ROWEEPRA compare with Keppra and other levetiracetam products?

Attribute	ROWEEPRA immediate release	Keppra immediate release	Extended-release levetiracetam	Orally disintegrating levetiracetam
Active ingredient	Levetiracetam	Levetiracetam	Levetiracetam	Levetiracetam
Market status	Generic	Branded or authorized-generic history	Separate modified-release segment	Differentiated dosage form
Main value driver	Price, availability, formulation usability	Brand recognition and historical clinical use	Once-daily convenience	Swallowing and administration convenience
Excipient opportunity	Cost, taste, coating, supply resilience	Brand-specific formulation and packaging	Release-control polymers and manufacturing	Superdisintegrants, taste masking, moisture control
Patent exposure	Generally low for immediate release	Historical and product-specific	Higher than immediate release	Product-specific
Biosimilar risk	None	None	None	None

ROWEEPRA’s strongest competitive position is likely a reliable, cost-efficient product with a better patient-use profile rather than a premium price based solely on conventional excipient selection.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate. The active ingredient is established, but high-volume production requires consistent blend uniformity, tablet weight control, dissolution, coating quality, and stability.

Key barriers include:

• Qualification of multiple excipient suppliers
• Control of lubricant mixing time
• Prevention of segregation in high-drug-load blends
• Tablet capping at high compression speeds
• Moisture protection for hygroscopic excipients
• Preservative effectiveness in oral liquids
• Flavor stability over shelf life
• Container-closure compatibility
• Bioequivalence after excipient substitution

Intellectual-property barriers are more significant for differentiated products than for conventional tablets. A novel taste-masking technology, ODT platform, or dosing device may support patent protection. The claims should be drafted around experimentally demonstrated performance rather than generic excipient categories.

What generic launch scenarios exist for ROWEEPRA?

Base case: conventional generic competition

Multiple suppliers compete on price, availability, and wholesaler coverage. Margins decline as more ANDA holders enter. Excipient strategy focuses on cost reduction and supply continuity.

Upside case: differentiated pediatric product

A sugar-free, better-tasting liquid or mini-tablet captures prescriber and caregiver preference. The product may sustain a premium if supported by usability data and reliable distribution.

Specialty case: institutional supply

A manufacturer wins hospital or government contracts through unit-dose packaging, dosing devices, and stable supply. The excipient formulation remains conventional, while packaging and service create the commercial distinction.

Risk case: formulation substitution failure

An excipient change alters dissolution, viscosity, taste, preservative performance, or bioequivalence. The result is regulatory delay, batch failure, or loss of a supply contract.

Key Takeaways

• ROWEEPRA is a levetiracetam product with limited immediate-release patent protection.
• Conventional tablet excipients provide low standalone differentiation and weak patent value.
• Pediatric oral-solution optimization is the strongest excipient-led opportunity.
• Taste masking, sugar reduction, dosing accuracy, and packaging usability have direct commercial relevance.
• Orally disintegrating tablets and mini-tablets offer a second differentiation path.
• Levetiracetam has no biosimilar exposure because it is a small-molecule drug.
• Generic competition makes manufacturing cost, supply resilience, and pharmacy access central to profitability.
• Strong formulation patents require defined excipient ranges and measurable performance data.
• Orange Book, Paragraph IV, and litigation analysis must be tied to the specific approved application and dosage form.
• The most defensible commercial strategy combines conventional immediate-release manufacturing with differentiated pediatric usability.

FAQs

Can ROWEEPRA be reformulated with different excipients?

Yes. A manufacturer may change inactive ingredients if the formulation remains compliant with FDA requirements, maintains quality and stability, and satisfies applicable bioequivalence and regulatory obligations.

Is a levetiracetam oral solution more commercially attractive than tablets?

Usually, yes, when the product targets pediatric patients or patients with swallowing difficulty. The commercial value depends on taste, dosing accuracy, preservative performance, packaging, and distribution.

Can excipient selection create a patent for ROWEEPRA?

It can, but conventional excipient substitutions generally have weak patent prospects. Stronger claims may arise from defined taste-masking systems, orally disintegrating technologies, release profiles, or device combinations supported by comparative data.

Does ROWEEPRA face biosimilar competition?

No. Levetiracetam is a chemically synthesized small molecule. Competitors generally use the ANDA generic-drug pathway rather than the biosimilar pathway.

Which excipients create the greatest regulatory risk in levetiracetam liquids?

Preservatives, flavors, high-load sweeteners, polyols, and viscosity modifiers create the greatest practical risk because they affect tolerability, microbial control, dosing accuracy, stability, and patient acceptance.

References

1. U.S. Food and Drug Administration. (n.d.). Levetiracetam drug products and prescribing information. FDA.

2. DailyMed. (n.d.). ROWEEPRA: Levetiracetam tablet, film coated and oral solution labeling. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).